Sale!

Theophylline Sustained-release Tablets 100mg (Theophylline SR Tablets Sawai® / テオフィリン徐放錠100mg「サワイ」)

元の価格は JPY ¥1,200 でした。現在の価格は JPY ¥1,056 です。

Japanese Xanthine-based Bronchodilator (Theophylline 100mg). Oral sustained-release tablet for bronchial asthma, asthmatic bronchitis, chronic bronchitis, and pulmonary emphysema. 100 tablets (10 tablets x 10). Mfd. by Sawai Pharmaceutical Co., Ltd., Japan.

Bulk deal
Quantity Discount Discounted price
5 - 9 8% JPY ¥1,104
10 - 19 12% JPY ¥1,056
20 + 18% JPY ¥984
SKU: THE-100-TAB Category:

Description

Product Overview / 商品概要

Theophylline Sustained-release Tablets 100mg “Sawai” (テオフィリン徐放錠100mg「サワイ」)
Generic: Theophylline / テオフィリン
Therapeutic Category: Xanthine-based Bronchodilator / キサンチン系気管支拡張剤
Manufactured by: Sawai Pharmaceutical Co., Ltd. / 沢井製薬株式会社

Composition & Specification / 組成・規格

Active Ingredient: Theophylline (JP) 100mg per tablet / 1錠中 日局テオフィリン 100mg
Additives: Light anhydrous silicic acid, Crystalline cellulose, Hydrogenated oil, Magnesium stearate, Hypromellose phthalate / 軽質無水ケイ酸、結晶セルロース、硬化油、ステアリン酸Mg、ヒプロメロースフタル酸エステル
Appearance: White, sustained-release uncoated tablet with score line; diameter 8.0mm, thickness 2.8mm, weight approx. 170mg; identification code: SW 128
外観: 白色、割線入り徐放性素錠、直径8.0mm、厚さ2.8mm、重量約170mg、識別コード: SW 128

Indications / 効能効果

EN: Bronchial asthma, Asthmatic (like) bronchitis, Chronic bronchitis, Pulmonary emphysema
JA: ○気管支喘息 ○喘息性(様)気管支炎 ○慢性気管支炎 ○肺気腫

Dosage and Administration / 用法用量

EN: Usual adult dose: 200mg (2 tablets) per dose; usual pediatric dose: 100–200mg (1–2 tablets) per dose; administered orally twice daily in the morning and before bedtime. For bronchial asthma, adults may receive 400mg (4 tablets) once daily before bedtime. Adjust dose according to age and symptoms.
JA: 通常、テオフィリンとして、成人1回200mg(本剤2錠)を、小児1回100~200mg(本剤1~2錠)を、1日2回、朝及び就寝前に経口投与する。また、気管支喘息については、テオフィリンとして成人1回400mg(本剤4錠)を、1日1回就寝前に経口投与することもできる。なお、年齢、症状に応じ適宜増減する。

Contraindications / 禁忌

EN: 2.1 Patients with a history of serious adverse reactions to this product or other xanthine-based agents. 2.2 Patients who have received adenosine (Adenoscan) within 12 hours.
JA: 2.1 本剤又は他のキサンチン系薬剤に対し重篤な副作用の既往歴のある患者 2.2 12時間以内にアデノシン(アデノスキャン)を使用する患者

Regulatory Information / 規制情報

Approval No.: 22400AMX00940000
Sales Started: July 1990 / 1990年7月
Classification Code: 872251
Storage: Store at room temperature / 室温保存
Shelf Life: 3 years / 3年

Packaging / 包装

Main Package (for sale): 100 tablets (10 tablets x 10) / 100錠(10錠×10)
Other Available Packages (by special order): PTP: 100 tablets (10 tablets x 10), 1,000 tablets (10 tablets x 100); Bulk: 1,000 tablets

Full product insert (添付文書) is attached as a downloadable PDF. For detailed precautions, drug interactions, and safety information, please refer to the official package insert.

Additional information

重さ 0.15 kg

Reviews

There are no reviews yet.

Be the first to review “Theophylline Sustained-release Tablets 100mg (Theophylline SR Tablets Sawai® / テオフィリン徐放錠100mg「サワイ」)”

メールアドレスが公開されることはありません。 が付いている欄は必須項目です

Export from Japan — Theophylline Sustained-release Tablets 100mg (Theophylline SR Tablets Sawai®

🏭 Supply & Origin

  • Country of Origin: Japan
  • Regulatory Standard: PMDA (Japan) / GMP Compliant
  • Pharmacopoeia: Japanese Pharmacopoeia (JP)
  • Supplier: Mate Co., Ltd. — Licensed Pharmaceutical Wholesaler (License No. B14309, Osaka)
  • Supply Capacity: Full-line sourcing through Japan's regulated distribution channels

🚚 Shipping & Trade Terms

  • Incoterms: FOB Kansai International Airport (KIX)
  • Shipping: Air freight via B/L or AWB
  • Payment: 100% T/T in advance
  • Lead Time: 2-4 weeks after payment confirmation
  • Available Regions: EU, LATAM, APAC, Middle East, Africa

Request a Quotation

For pricing, MOQ, and regulatory documentation, contact our export team:

Email: kurimoto@mate-osaka.co.jp
Tel: +81-72-665-5736

All exports are conducted through proper regulatory procedures including customs clearance, B/L or AWB documentation, and T/T advance payment. We do not engage in hand-carry, cash transactions, or sales to unlicensed parties.